Monopar Therapeutics (MNPR) Invested Capital: 2016-2020
Historic Invested Capital for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to $17.6 million.
- Monopar Therapeutics' Invested Capital rose 279.67% to $17.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $17.6 million, marking a year-over-year increase of 279.67%. This contributed to the annual value of $12.6 million for FY2019, which is 82.53% up from last year.
- Monopar Therapeutics' Invested Capital amounted to $17.6 million in Q3 2020, which was up 43.91% from $12.2 million recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Invested Capital registered a high of $17.6 million during Q3 2020, and its lowest value of $2.8 million during Q4 2016.
- Over the past 3 years, Monopar Therapeutics' median Invested Capital value was $8.1 million (recorded in 2018), while the average stood at $9.3 million.
- As far as peak fluctuations go, Monopar Therapeutics' Invested Capital plummeted by 38.95% in 2019, and later spiked by 279.67% in 2020.
- Over the past 5 years, Monopar Therapeutics' Invested Capital (Quarterly) stood at $2.8 million in 2016, then surged by 239.78% to $9.6 million in 2017, then dropped by 28.08% to $6.9 million in 2018, then surged by 82.53% to $12.6 million in 2019, then soared by 279.67% to $17.6 million in 2020.
- Its last three reported values are $17.6 million in Q3 2020, $12.2 million for Q2 2020, and $12.4 million during Q1 2020.